Zenagamtide

Zenagamtide, previously called amycretin, is an experimental weight-loss and diabetes drug from Novo Nordisk, the company behind Ozempic and Wegovy. It is being studied as a weekly injection and a daily pill.

Early results have drawn attention, particularly the weight loss seen with the injection. Larger studies are now underway to find out how well it works and how people tolerate it over time. It remains an investigational medicine. Novo Nordisk

What Is Zenagamtide, and How Does It Work?

Zenagamtide is a lab-made peptide designed to copy two signals that help tell your brain you've eaten enough:

• GLP-1 comes from your gut after a meal. It helps you feel full and helps control blood sugar.
• Amylin is released with insulin from your pancreas. It also helps signal that you've had enough to eat.

Zenagamtide acts on both systems in one molecule. It also activates a related target called the calcitonin receptor. These targets are like buttons on cells that receive signals. Novo Nordisk research

Why Did Amycretin Become Zenagamtide?

Amycretin was its development name. The World Health Organization proposed zenagamtide as its generic name in 2025, and Novo now uses that name.

They refer to the same drug. That explains why an older article might say amycretin while a newer study says zenagamtide. WHO naming record, Novo's annual report

How Much Weight Did People Lose?

The weekly injection

An early study enrolled 125 adults with overweight or obesity at one US clinic. In the highest-dose group, estimated average weight loss reached 24.3% after 36 weeks, compared with 1.1% in the placebo group, which received an injection without the active drug.

For perspective, 24% of 220 pounds is about 53 pounds.

That is a substantial result, but the study was small and many people withdrew for various reasons. The headline figure does not tell us what most people would lose in everyday use. Published injection study

The daily pill

In a separate early study, the highest-dose pill group lost an average of 13.1% after 12 weeks, compared with 1.2% on placebo.

That study was primarily looking at safety and how the body handled the medicine. The weight findings were encouraging, but they need confirmation in larger studies. Published pill study

These results do not settle whether the injection works better than the pill. The studies lasted different lengths of time and were designed differently.

People with type 2 diabetes

Both forms also lowered blood sugar in a 36-week study involving adults with type 2 diabetes. In the highest-dose injection group, average weight loss reached 14.6%, compared with 2.1% on placebo.

The findings suggest that zenagamtide could help with both weight and blood sugar. They are still study results, rather than a prediction of what it would do for you. Diabetes study results

What Side Effects Have Been Reported?

The most common problems have involved the stomach and gut, including nausea, vomiting and diarrhea. Most were described as mild or moderate, but some people stopped treatment because of them. Published injection study

In the diabetes pill study, seven people receiving zenagamtide had serious medical events, compared with none receiving placebo. The study calls these serious adverse events. That means they happened during the trial; it does not, by itself, establish that the drug caused them. Published diabetes pill study

Long-term safety remains an open question. Larger studies will help show how often problems occur and whether people can stay on treatment.

What Are the Larger Studies Looking At?

Zenagamtide has moved into phase 3, the larger studies used to help regulators decide whether a medicine should be approved.

The program includes studies of weight loss and diabetes, along with conditions such as sleep apnea, knee arthritis and heart failure. Testing it for those conditions does not mean it has been shown to treat them. ClinicalTrials.gov study listings

Common Questions About Zenagamtide

Is it better than tirzepatide, retatrutide or Wegovy?

We don't know yet. The available results do not establish that zenagamtide works better than tirzepatide or retatrutide.

Studies comparing it directly with semaglutide, the medicine in Wegovy, are underway. Until those results arrive, comparing headlines from separate trials can give the wrong impression. AMAZE 7, AMAZE 8

Is it the same as CagriSema?

No. CagriSema combines two medicines: cagrilintide and semaglutide. Zenagamtide is one molecule designed to act on both the amylin and GLP-1 systems.

They have some targets in common, but that does not make them interchangeable. Novo's development overview

Are there studies on switching from another weight-loss medicine?

Yes. Two small studies are examining the switch from semaglutide or tirzepatide to zenagamtide. They focus on side effects and how the body handles the medicine.

They are not instructions for switching on your own. If your current treatment is not working well for you, speak with the clinician who prescribes it. Semaglutide switching study, Tirzepatide switching study

Can I buy zenagamtide or amycretin online?

You may find products advertised under either name. A seller using the name does not establish that its product matches the medicine used in Novo's clinical trials.

Taylor Tides does not sell zenagamtide. There is no approved dose for routine treatment, and the doses used in studies should not be treated as instructions for an online product.

How can I find a clinical trial?

Search ClinicalTrials.gov for zenagamtide, amycretin or its research code, NNC0487-0111. Look for studies marked Recruiting, check the locations and contact the study team.

Each trial has its own requirements. Ask whether your current medicines affect eligibility, what visits are involved and whether there are any costs or payments for participating.

When might it become available?

Novo has discussed a possible 2029 launch, but that is a company projection, not an approved release date. The studies and regulatory review will determine what happens next. Novo's September 2026 presentation

If you are looking for help with weight or blood sugar now, ask your clinician about the options already available while studies continue on zenagamtide.